Descartes-08

Phase 2Cell therapy

CCartesian Therapeutics

Descartes-08 is one of 112 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

MyositisActive, not recruiting

Multiple MyelomaActive, not recruiting

Myasthenia GravisActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

MyositisPhase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Myasthenia GravisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Descartes-08

CCartesian Therapeutics

Phase 2

1 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

Intron a

Systemic Therapy

1 9

Abecma

Bristol-Myers Squibb

Preclinical

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Systemic Lupus Erythematosus

NCT06038474

Q2 2027

Phase 2Not yet recruiting

Myositis

NCT07391605

Q4 2028

Phase 1/2Recruiting

Autoimmune Disorders

NCT07089121

Clinical

Trials by Indication[1]

Autoimmune Disorders1 trial

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Recruiting·CCartesian Therapeutics·Phase 1/2·NCT07089121·50 enrolled

Multiple Myeloma1 trial

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Terminated·CCartesian Therapeutics·Phase 2·NCT04816526·13 enrolled

Myasthenia Gravis1 trial

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Active, not recruiting·CCartesian Therapeutics·Phase 2·NCT04146051·30 enrolled

Myositis1 trial

Descartes-08 in Autoantibody Myositis

Not yet recruiting·CCartesian Therapeutics·Phase 2·NCT07391605·60 enrolled

Systemic Lupus Erythematosus1 trial

Descartes-08 for Patients With Systemic Lupus Erythematosus

Active, not recruiting·CCartesian Therapeutics·Phase 2·NCT06038474·6 enrolled

1 more indication

Myeloma1 trial

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Terminated·CCartesian Therapeutics·Phase 1·NCT03448978·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Descartes-08. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Descartes-08 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Descartes-08. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cartesian Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: CCartesian Therapeutics

Descartes-08

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2028

Trials by Indication[1]

Autoimmune Disorders1 trial

Multiple Myeloma1 trial

Myasthenia Gravis1 trial

Myositis1 trial

Systemic Lupus Erythematosus1 trial

Myeloma1 trial

References

Drug Info

Quick Facts

Related News